Nicotine Decreases Bradykinesia-rigidity in Haloperidol-treated Patients with Schizophrenia

Yang, Yen Kuang; Nelson, Linda M.; Kamaraju, Lakshmi S.; Wilson, William H.; McEvoy, Joseph P.

doi:10.1016/s0893-133x(02)00325-1

Cited by 28 publications

(24 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The positive correlation between mGluR5 and antipsychotic use that we found in nonsmokers seems to support the selfmedication hypothesis with regard to medication side effects. In haloperidol-treated patients with schizophrenia, the application of nicotine through transdermal patches reduced bradykinesia-rigidity (Yang et al, 2002). Because the majority of subjects included in our study used atypical antipsychotics, one might conclude that this nicotine effect is irrelevant.…”

Section: Discussionmentioning

confidence: 86%

Metabotropic glutamate receptor 5 neuroimaging in schizophrenia

Akkus

Treyer

Ametamey

et al. 2017

Schizophrenia Research

View full text Add to dashboard Cite

The metabotropic glutamate receptor 5 (mGluR5) is a promising drug target for the treatment of schizophrenia. In this study, we compared mGluR5 distribution volume ration (DVR) in subjects with schizophrenia and healthy controls. Given our previous findings, we matched samples for gender, age, and smoking status. Binding to mGluR5 was determined using positron emission tomography and [ 11 C]ABP688, which binds to an allosteric site with high selectivity. DVR in the 15 individuals with schizophrenia did not differ from that of the 15 controls. In both groups, smoking was associated with marked global reductions in mGluR5 availability (on average 23.8%). In nonsmoking subjects with schizophrenia, there was a positive correlation between mGluR5 DVR in the medial orbitofrontal cortex and the use of antipsychotic drugs (r = 0.9, p =0.019). Because antipsychotic drugs such as clozapine appeared to have indirect effects on mGluR5 signaling, our findings may be clinically relevant. They also provide promising leads for elucidating the high comorbidity between schizophrenia and tobacco addiction. Low mGluR5 DVR in smokers my represent a risk factor for schizophrenia. Alternatively, smoking may counteract the potential upregulation of mGluR5 by antipsychotic drugs.

show abstract

Section: Discussionmentioning

confidence: 86%

Metabotropic glutamate receptor 5 neuroimaging in schizophrenia

Akkus

Treyer

Ametamey

et al. 2017

Schizophrenia Research

View full text Add to dashboard Cite

show abstract

“…This is consistent with the hypothesis of Mancuso et al (1999), whereby the nicotine-induced improvement in attention is a consequence of nicotine acting to 'lock the brain into the attentional processing mode and so there are fewer lapses in attention', hence fewer errors of omission might be expected. However, an improvement in accuracy (proportion correct) following nicotine administration has also been observed in subjects displaying impaired attentional function, associated with schizophrenia, Alzheimer's disease, and attention deficit hyperactivity disorder (White and Levin, 1999;Shytle et al, 2002;Yang et al, 2002). The 5-CSR task was developed to examine sustained attention in rodents (Carli et al, 1983) and is regarded as being analogous to the CPT (Jones and Higgins, 1995).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, it has been suggested that nicotine can lock the brain into an attentional processing mode whereby there are fewer lapses in attention and therefore less omissions (Mancuso et al, 1999). These observations may underlie the ability of nicotine to enhance attention and improve the symptomatology of various human diseases including schizophrenia (Yang et al, 2002), Alzheimer's disease (White and Levin, 1999), attention deficit hyperactivity disorder (Shytle et al, 2002), Parkinson's disease (O'Neill et al, 2002), and Tourette's syndrome (Sanberg et al, 1997).…”

Section: Introductionmentioning

confidence: 99%

Nicotine Improves Sustained Attention in Mice: Evidence for Involvement of the α7 Nicotinic Acetylcholine Receptor

Young

Finlayson

Spratt

et al. 2004

Neuropsychopharmacol

209

174

View full text Add to dashboard Cite

In humans, nicotine has been shown to improve attention in both normal and impaired individuals. Observations in rats reflect some, but not all aspects of the nicotine-induced improvements in humans. To date these findings have not been replicated in mice. To examine the effect of nicotine on sustained attention in mice, we have established a version of the 5-choice serial reaction-time (5-CSR) task with graded levels of difficulty, based upon spatial displacement and a variable intertrial interval. Using this paradigm, microgram doses of nicotine produced a consistent reduction in the level of omissions and an improvement in proportion correct in normal mice. This improvement in sustained attention was made irrespectively of whether mice had previously received nicotine. In an attempt to elucidate which nicotinic acetylcholine receptor (nAChR) subtype(s) mediate this effect, we examined the performance of a7 nAChR knockout (KO) mice in the 5-CSR task. a7 nAChR KO mice not only acquired the task more slowly than their wild-type littermates, but on attaining asymptotic performance, they exhibited a higher level of omissions. In conclusion, by increasing the level of task difficulty, the performance of mice was maintained at sufficiently low levels to allow a demonstrable improvement in performance upon nicotine administration. Furthermore, as a7 KO mice are clearly impaired in the acquisition and asymptotic performance of this task, the a7 nAChR may be involved in mediating these effects of nicotine.

show abstract

“…In fact, this phenomenon has been demonstrated with one currently indicated treatment for schizophrenia, clozapine, as discussed in the next section. Yang et al (2002) Nicotine patch improves tremor and bradykinesia-rigidity symptoms in smokers with schizophrenia. Smith et al (2002) Smoking cigarettes does not increase tardive dyskinesia, extrapyramidal or parkinsonian symptoms.…”

Section: Nicotine As a Prototypic Agonistmentioning

confidence: 99%

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

2004

View full text Add to dashboard Cite

show abstract

Nicotine Decreases Bradykinesia-rigidity in Haloperidol-treated Patients with Schizophrenia

Abstract: We applied nicotine 21 mg and matching placebo transdermal patches to thirty haloperidol-treated patients with schizophrenia who smoked. Clinical assessments of bradykinesia-rigidity were lower during nicotine patch administration than during placebo patch administration.

Cited by 28 publications

References 9 publications

Metabotropic glutamate receptor 5 neuroimaging in schizophrenia

Metabotropic glutamate receptor 5 neuroimaging in schizophrenia

Nicotine Improves Sustained Attention in Mice: Evidence for Involvement of the α7 Nicotinic Acetylcholine Receptor

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

Contact Info

Product

Resources

About